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Abstract  35 
 36 
Porcine reproductive and respiratory syndrome virus (PRRSV) is a widespread pathogen of 37 
pigs causing significant economic losses to the swine industry. The expanding diversity of 38 
PRRSV strains makes the diagnosis, control and eradication of the disease more and more 39 
difficult. In the present study, the authors report the full genome sequencing of a Type 2 40 
PRRSV strain isolated from piglet carcasses in Hungary. Next generation sequencing was 41 
used to determine the complete genome sequence of the isolate (PRRSV-42 
2/Hungary/102/2012). Recombination analysis performed with the available full-length 43 
genome sequences showed no evidence of such event with other known PRRSV. Unique 44 
deletions and an insertion were found in the nsp2 region of PRRSV-2/Hungary/102/2012 45 
when it was compared to the highly virulent VR2332 and JXA-1 prototype strains. A majority 46 
of amino acid alterations in GP4 and GP5 of the virus were in the known antigenic regions 47 
suggesting an important role for immunological pressure in PRRSV-2/Hungary/102/2012 48 
evolution. Phylogenetic analysis revealed that it belongs to lineage 1 or 2 of Type 2 PRRSV. 49 
Considering the lack of related PRRSV in Europe, except for a partial sequence from Slovakia, 50 
the ancestor of PRRSV-2/Hungary/102/2012 was most probably transported from North-51 
America. It is the first documented type 2 PRRSV isolated in Europe that is not related to the 52 
Ingelvac MLV. 53 
54 
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Introduction 55 
 56 
Porcine reproductive and respiratory syndrome emerged at the same time in Europe (early 57 
1990s, Wenswoort et al., 1991) and North America (late 1980s, Keffaber 1989), and since 58 
then, the virus (porcine reproductive and respiratory syndrome virus, PRRSV) has rapidly 59 
spread throughout the world, and became endemic in almost every major swine producing 60 
country.  61 
 PRRSV is a member of the Arteriviridae family within the order Nidovirales 62 
(Cavanagh 1997; Faaberg et al., 2011). It has a positive-sense single stranded RNA genome of 63 
15kb in length that encodes 10 open reading frames (Snijder and Meulenberg, 1998; Firth et 64 
al. 2011; Johnson et al. 2011). Comparative nucleotide sequence analyses revealed that 65 
PRRSV strains can be classified into two distinct genotypes: type 1 (formerly named as 66 
European) and type 2 (formerly named as North American). Remarkably, the two genotypes 67 
have only 50–60% nucleotide identity (Allende et al. 1999).  68 
 A comprehensive phylogenetic study of the North American type 2 PRRSV strains has 69 
recently been published that was based on the Bayesian analysis of 8624 ORF5 sequences 70 
(Shi et al. 2010b). Based on their results, the authors defined 9 monophyletic lineages within 71 
this genotype and established a set of reference sequences representing the principal diversity 72 
of type 2 sequences. 73 
 Type 2 strains were first introduced to Europe in 1996 by the use of a modified live 74 
virus (MLV) vaccine in Denmark (Botner et al, 1997). Soon after its introduction into the 75 
population, the MLV strain, a cell culture adapted variant of the type 2 prototype VR2332 76 
strain, spread horizontally and vertically among pigs and herds as well, and showed multiple 77 
genetic mutations (Nielsen et al. 2001). The vaccine is currently registered in Germany, 78 
Poland, The Netherlands, Belgium, Denmark, Spain and Lithuania, and under special import 79 
agreements in Slovakia. According to latest results, confirmed by full genome sequence 80 
analyses in Denmark, the vast majority of the type 2 strains found in Europe are genetically 81 
related (>95% ORF5 nucleotide identity) to the aforementioned vaccine (Kvisgaard et al., 82 
2013). A more recent study involving numerous type 2 ORF5 sequences from throughout 83 
Europe revealed a small group of sequences that are 91–94 % similar to the Ingelvac MLV, 84 
and can not unequivocally be attributed to the vaccine (Stadejek et al, 2014). 85 
 The aim of our study was to characterize a member of the third group of European 86 
type 2 sequences, that are 88% or less similar to the Ingelvac strain on ORF5, confirming the 87 
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wild type nature of these strains (Balka et al. 2008). These sequences were first identified in 88 
2005 in multiple sites of a swine breeding company with mild clinical signs of PRRS. 89 
 90 
Materials and methods 91 
 92 
Origin of the isolate 93 
Lung tissue and lymph node samples were obtained from the carcass of a young growing pig 94 
originating from an endemically PRRS positive herd, where our previous investigations 95 
verified the presence of type 2 PRRSV (Balka et al., 2008). No signs of an acute outbreak 96 
were present. Only mild to moderate respiratory symptoms were observed among the young 97 
fatteners. No significant reproductive disorders were reported at the time of sampling. 98 
 99 
Cells and viruses 100 
Porcine alveolar macrophages (PAMs) obtained from PRRSV-free piglets were cultured in 101 
RPMI-1640 medium supplemented with 10% (v/v) fetal bovine serum, 100 U/ml penicillin, 102 
100 µg/ml streptomycin and 2 mM L-glutamine (Sigma-Aldrich, Saint Louis, MO, USA) at 103 
37°C and 5% CO2. To culture PRRSV-2/Hungary/102/2012, approximately 0.5 g pieces of 104 
lung tissue were taken from dead pigs. The lung and tracheobronchial lymph node samples 105 
originating from the endemically infected farm were homogenized with Tissue Lyser (Qiagen, 106 
Hilden, Germany) in sterile phosphate-buffered saline (PBS) containing antibiotics and 107 
antimycotics, to obtain a 50% w/v suspension. After complete homogenization, the samples 108 
were centrifuged at 5000×g for 10 min to remove cellular debris. Cell-free supernatants were 109 
frozen at –80°C for RNA isolation. PAMs were inoculated with 100 µl of supernatant and 110 
incubated for five days. Besides the periodic examination of the cell cultures for the presence 111 
of cytopathic effects, real-time RT-PCR analysis (Balka et al., 2009) was also applied on the 112 
supernatants to confirm the growth of the virus. Cell-free supernatants were stored at –80°C 113 
for RNA isolation. 114 
 115 
RNA isolation and cDNA synthesis 116 
RNA was isolated with QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) from the 117 
original tissue homogenates and PAM cell culture supernatants. cDNA was generated using 118 
Superscript III First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA, USA) 119 
kit and a T20 primer, according to the protocol of the manufacturer.  120 
 121 
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Overlapping PCR products for next generation sequencing 122 
The genome of PRRSV-2/Hungary/102/2012 was amplified in five overlapping parts, 123 
(similarly to Kvisgaard et al., 2013b), using the Phusion II HotStart PCR kit (Thermo 124 
Scientific, Waltham, MA, USA), in 25 µl final volume with 1 µl of cDNA template, in 1× GC 125 
buffer in the presence of 4% DMSO. Amplification was performed using the following 126 
gradient PCR program: 98°C 1’, 35 × [98°C 20”, 54-72°C (gradient ramp: 2°C) 20”, 72°C 5’], 127 
72°C 5’. The primer pairs used for the amplification of the different fragments are listed in 128 
Table 1. Primers were designed using Primer3Plus (Untergasser et al., 2007). PCR fragments 129 
were purified from agarose gel slices by the QIAquick Gel Extraction Kit (Qiagen, Hilden, 130 
Germany). For determination of both ends of the genome, the 5′ RACE System for Rapid 131 
Amplification of cDNA Ends, version 2.0 (Invitrogen, Carlsbad, CA, USA) as well as a 132 
forward ORF7 primer (Balka et al., 2008) and the T20 primer were applied. 133 
 134 
Next generation sequencing (NGS) 135 
An equimolar mixture of the overlapping PRRSV PCR products was used as template for next 136 
generation sequencing. In brief, a DNA library was prepared using the NEBNext® Fast DNA 137 
Fragmentation & Library Prep Set for Ion Torrent (New England Biolabs, Beverly, MA, 138 
USA) with the Ion Torrent Xpress barcode adapters (Life Technologies, Carlsbad, CA, USA) 139 
according to the protocol recommended by the manufacturers. The emulsion PCR and 140 
subsequent template enrichment were carried out with the Ion OneTouch™ Template Kit on a 141 
OneTouch v1 instrument and an Ion OneTouch™ ES pipetting robot, respectively. 142 
Sequencing was carried out on a 316 chip using the Ion Torrent semiconductor sequencing 143 
equipment (Ion Personal Genome Machine® (PGMTM); Life Technologies). Sequences were 144 
assembled and aligned with SeqMan Ngen software (Lasergene, Madison, WI, USA). 145 
 146 
Phylogenetic analysis 147 
PRRSV whole genome sequences in Genbank, including 16 type 1 and 199 type 2 field, 148 
vaccine and laboratory strains, were obtained from the continents of Europe, Asia, and North 149 
America (n=215, Table 2). PRRSV whole genome alignment was done with the MUltiple 150 
Sequence Comparison by Log-Expectation (MUSCLE) algorithm (Edgar, 2004) in Geneious 151 
Pro 6.1.7 using default settings. The evolutionary history was inferred using the Maximum 152 
Likelihood method based on the Tamura-Nei model (Tamura and Nei, 1993). The tree with 153 
the highest log likelihood (-266940) is shown. Initial trees for the heuristic search were 154 
obtained by applying the Neighbor-Joining method to a matrix of pairwise distances estimated 155 
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using the Maximum Composite Likelihood (MCL) approach. The tree is drawn to scale, with 156 
branch lengths measured in the number of substitutions per site. The analysis involved 215 157 
genome sequences. All positions containing gaps and missing data were eliminated. There 158 
were a total of 12911 positions in the final dataset. Evolutionary analyses were conducted in 159 
MEGA6 (Tamura et al., 2013). 160 
Additional type 2 PRRSV ORF5 sequences were added to the database to enlarge total 161 
genetic diversity. ORF5 nucleotide sequences were aligned with MUSCLE and phylogeny 162 
was determined by maximum likelihood in MEGA as described above. The closest known 163 
relatives to PRRSV-2/Hungary/102/2012 were determined by BLAST analysis in Genbank 164 
(Altschul et al., 1990).  165 
Recombination analysis of the complete genome was performed with Recombination 166 
Analysis Tools (RAT) (Etherington et al., 2005) using the 215 Genbank accessions as 167 
references. Insertion-deletion analysis was visualized by the alignment of the Hungarian 168 
isolate to the type 2 prototype strain VR2332 (acc. number: EF536003) and to the highly 169 
pathogenic Chinese strain CHN-JXA1 (acc. number: EF112445). 170 
The distribution of N-glycosylation sites was determined using NetNGlyc 1.0 Server 171 
web utility (http://www.cbs.dtu.dk/services/NetNGlyc/). The antigenic regions, T and B cell 172 
epitopes were determined as described using an amino acid alignment with the reference 173 
strains VR2332, Ch-1a (acc. number:AY032626) and NVSL 97-7895 (acc. number: 174 
AY545985) (Diaz et al., 2009; de Lima et al., 2006; Mokhtar et al., 2014; Plagemann et al., 175 
2002; Ostrowski et al., 2002; Vashisht et al., 2008; Zhou et al., 2009). 176 
 177 
Results 178 
 179 
Tissue homogenate supernatants of pig carcasses originating from an endemically infected 180 
herd were used to inoculate PAM cells in order to isolate and amplify the PRRSV strain for 181 
further analysis. Virus induced cytopathic effect, i.e. cell lysis was observed from the 2nd day 182 
post infection and reached 100% by the 5th day. Marked decrease in the Ct values was 183 
observed in the real-time RT-PCR reactions performed on the infected cell culture 184 
supernatants, compared to the original tissues confirming the increase in viral RNA copy 185 
number. 186 
 NGS was performed on the equimolar mixture of five overlapping fragments of the 187 
entire genome that were amplified by routine RT-PCR applying high fidelity DNA 188 
polymerase. After the assembly and alignment of the sequence fragments, the full length 189 
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sequence of PRRSV-2/Hungary/102/2012 was found to be 15321 nt in length (GenBank acc. 190 
number: KM514315). The untranslated 5’ and 3’ends (UTRs) were 189 nt and 151 nt, 191 
respectively. The size of the 5’UTR was identical with that of PRRSV DK-2003-2-3 192 
(Genbank Accession No.: KC862584.1) with 12 nt differences in the sequences. The size of 193 
the 3’end of PRRSV (PRRSV-2/Hungary/102/2012) was identical with that of PRRSV DK-194 
2004-1-7-Pl (Genbank Accession No.: KC862578.1) with four nt difference.  195 
The phylogenetic analysis of the whole genome of PRRSV-2/Hungary/102/2012 and 196 
215 other full PRRSV genomes showed that it was a novel type 2 PRRSV isolate that was 197 
phylogenetically close to the progenitor type 2 PRRSV, and not related to VR2332 or 198 
Ingelvac PRRSV MLV (Figure 1.).  199 
The ORF5 dendrogram (Figure 2a) that included a larger dataset of other ORF5 200 
sequences showed that PRRSV-2/Hungary/102/2012 was clustered in lineage 2 PRRSV, 201 
which may have originated in Eastern Canada where the earliest isolates were found.  202 
BLAST comparisons of the full genome to Genbank accessions showed that even the 203 
most similar strain, VR2385 (JX044140), was only 87% identical. Similarly, BLAST analysis 204 
of the ORF5 sequences in Genbank showed that the 11 most similar hits were only 91 to 92% 205 
identical, and almost all of these strains were isolates from the early 2000’s. Interestingly, the 206 
set included a Canadian PRRSV strain IAF 93-2616 (U64932), isolated in 1993, early in the 207 
history of PRRSV. To more stringently delineate the origin of PRRSV-2/Hungary/102/2012, 208 
the nearest BLAST hits were incorporated with lineage 1 and lineage 2 ORF5 sequences and 209 
re-analyzed. The results, shown in Figure 2b, indicate that PRRSV-2/Hungary/102/2012 210 
clusters near the divergence of lineages 1 and 2. The most similar matches to PRRSV-211 
2/Hungary/102/2012, at 92% nucleotide identity (solid circles) were present in both lineages.  212 
To exclude the possibility that PRRSV-2/Hungary/102/2012 was a recombination 213 
product involving unknown parental viruses or European progeny of the type 2 PRRSV 214 
Ingelvac MLV vaccine, a recombination analysis was performed. The RAT analysis showed 215 
no evidence of recombination anywhere in the genomes of all 216 whole genome sequences 216 
available to us (data not shown). 217 
 PRRSV-2/Hungary/102/2012 has deletions of 10 amino acids (VR3223 aa 314-323) 218 
and 9 amino acids (VR2332 aa 792-800) in the nsp2 that were not present in prototype strain 219 
VR2332 or the prototype high pathogenicity Chinese strain JXA1 (Figure 3). By contrast, 220 
there was a 9 aa insertion in the nsp2 (102HU aa 795-803) that was not present in VR2332 or 221 
JXA1. These differences were due to in-frame insertions/deletions at the corresponding 222 
coding regions of the genomic RNA (Figure 3). 223 
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 The antigenic regions (ARs) and glycosylation sites within GP2, GP3, GP4 and GP5 224 
proteins of PRRSV-2/Hungary/102/2012 have been analyzed and compared to references 225 
VR2332, Ch-1a and NVSL 97-7895. 226 
At least four B cell epitopes or ARs have been inferred within GP2 (de Lima et al., 227 
2006; Vanhee et al., 2011). The presence of two antigenic regions (AR41-55 and AR123-135) 228 
were confirmed in both type 1 and type 2 PRRSV, while the presence of AR92-103, and the 229 
AR206-217 were confirmed only in the type 1 prototype strain Lelystad virus (de Lima et al., 230 
2006; Vanhee et al., 2011). However, the two latter regions are conservative between type 1 231 
and type 2 viruses, so it is possible that they are recognized as B cell epitopes in the type 2 232 
PRRSV strains as well. Only one amino acid (aa) substitution was detected in AR92-103 233 
between PRRSV-2/Hungary/102/2012 and the reference strains. No aa substitution was 234 
detected in AR123-135 and AR206-217, and four aa substitutions were observed between the less 235 
similar NVSL 97-7895 and 102HU in AR41-55. Two N-glycosylation sites are present in GP2 236 
(Das et al., 2010). The position of these glycosylation sites remained similar in all 237 
investigated strains though there are some aa changes in the glycosylation recognition 238 
sequence of PRRSV-2/Hungary/102/2012 when compared to the reference strains (Figure 4A).  239 
 Four experimentally proven antigenic regions were shown within GP3 (de Lima et al., 240 
2006; Zhou et al., 2006, Wang et al., 2014). The AR51-105 contains at least five overlapping 241 
epitopes (AR51-65, AR67-78, AR73-85, AR81-95, AR91-105) recognized by B cells. Surprisingly, this 242 
region is conservative: only five aa differences were detected among the investigated strains 243 
and there were only three aa changes between PRRSV-2/Hungary/102/2012 and any of the 244 
analyzed strains. AR32-46 and AR111-125 are completely conserved, with no aa substitutions 245 
observed in this region. AR137-159, a variable region of GP3, had four aa substitutions in the 246 
AR of GP3 of PRRSV-2/Hungary/102/2012. The position of the seven conserved N-247 
glycosylation sites predicted in GP3 is similar to the reference strains (Das et al., 2010) 248 
(Figure 4B). 249 
 The presence of two T cell epitopes (Díaz et al., 2008) and one B cell epitope (de Lima 250 
et al., 2006) were reported within GP4. AR51-65 is a hypervariable region of GP4; five aa 251 
substitutions were detected in that of PRRSV-2/Hungary/102/2012 compared to the GP4 of 252 
the reference strains. A putative T cell epitope7-15 (Tce7-15) is recognized by MHCII (described 253 
in PRRSV strain L-450) (Díaz et al., 2008). This sequence is very divergent in PRRSV-254 
2/Hungary/102/2012, as it contains three aa substitutions in the 9 aa epitope. Tce170-178, 255 
recognized by MHCI (same reference as in previous sentence), has two aa substitutions in 256 
PRRSV-2/Hungary/102/2012 compared to the other strains. While four N-glycosylation sites 257 
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in this protein were recognized in the reference strains (Das et al., 2010), an additional, fifth 258 
N-glycosylation site was observed within AR51-65 in GP4 of PRRSV-2/Hungary/102/2012 259 
(Figure 4C). 260 
 The presence of at least six B cell epitopes (de Lima et al., 2006; Zhou et al., 2009) 261 
and three T cell epitopes were reported within GP5. Three antigenic regions in the C-terminus 262 
of GP5 protein are conserved (Zhou et al., 2009). AR166-181 and AR192-200 of PRRSV-263 
2/Hungary/102/2012 have only one aa substitution each and AR149-156 is completely conserved 264 
compared to the reference strains. Two ARs in the N-terminus of the protein are variable. 265 
Three aa substitutions were observed in AR1-15 and five aa substitutions in AR27-35 (Thaa et al., 266 
2013). A B cell epitope (AR37-51) of the GP5 is highly conserved (Plagemann et al., 2002; 267 
Ostrowski et al., 2002), only one aa substitution was found between PRRSV-268 
2/Hungary/102/2012 and Ch1a. The three T cell epitopes are also highly conserved in GP5. 269 
Tce60-74, which is recognized by MHCII (described in PRRSV strain L-450), and Tce149-163 270 
(described in NADC-9 and NVSL-14) do not contain aa substitutions in PRRSV-271 
2/Hungary/102/2012 when compared to the reference strains (Díaz et al., 2008; Vashisht et al., 272 
2008; Mokhtar et al., 2014). In Tce115-126,  which is recognized by MHCI (described in 273 
PRRSV strain L-450), one aa substitution was observed among the investigated strains (Díaz 274 
et al., 2008; Vashisht et al., 2008; Mokhtar et al., 2014). GP5 contains five potential N-275 
glycosylation sites in PRRSV-2/Hungary/102/2012. Two sites (N44 and N51) are highly 276 
conserved (Israrul et al., 2006; Meulenberg, 2000) and were found within AR37-51. The other 277 
three glycosylation sites (N30, N34 and N35) were within the heterogeneous AR27-35 (Figure 278 
4D). 279 
 280 
Discussion 281 
 282 
Type 2 PRRSV strains are predominant in North America and Asia while in Europe fully 283 
sequenced type 2 strains were closely related to Ingelvac PRRS MLV (Kvisgaard et al. 2013a). 284 
In case of ORF5 sequences of European type 2 strains they were at least 91% identical to the 285 
aforementioned vaccine strain. Our previous results of genetic analysis of a PRRSV Type 2 286 
ORF5 sequence from Hungary and a similar one in Slovakia (one of Hungary’s neighboring 287 
countries) indicated that there are type 2 strains circulating in these countries that are much 288 
more distant to Ingelvac PRRS MLV. In this study we described the genetic, and antigenic 289 
characteristics of the complete genome of the first European, wild, type 2 isolate, which is 290 
clearly not related to Ingelvac PRRS MLV. Moreover, the genome of PRRSV-291 
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2/Hungary/102/2012 was only 87% identical to the most similar genome available in 292 
GenBank proving its unique status. 293 
Phylogenetic analyses performed with the whole genome of PRRSV-2/Hungary/102/2012 and 294 
215 GenBank full genome accessions, as well as ORF5 sequences from type 2 PRRSV 295 
isolates globally, revealed that it is a member of an ancient lineage 1 or lineage 2 cluster 296 
whose earliest sequence was reported from Eastern Canada in the early 1990’s (Brar et al., 297 
2011; Shi et al., 2010b).  298 
Our previous analyses with the use of limited sequences suggested that it might belong 299 
to lineage 1 (quite similar to lineage 2) (Stadejek et al., 2014) indicating the importance of 300 
using an appropriate, broad-range reference set when genotyping otherwise similar type 2 301 
PRRSV strains. 302 
The Eastern Canadian origin of both lineages 1 and 2 and their cross-border 303 
transmission primarily to the North Central USA (Shi et al., 2010b, Brar et al., 2011) suggests 304 
that our Hungarian strain may have become established in eastern Europe following the 305 
introduction of pigs or germplasm harboring a PRRSV from these regions within the past 10 306 
to 15 years. It then evolved independently for an extended period of time to reach its current 307 
level of divergence. As no reliable data are available about pig importation to Hungary from 308 
that period, it cannot be excluded that a wild-type 2 PRRSV was introduced elsewhere in the 309 
region and then transported to Hungary.  310 
Jackova et al. (2013) published a partial 432 base ORF5 sequence corresponding to the 311 
ectodomain of GP5 of a Slovakian isolate from 2003 (strain 36M, acc. number: KC522648), 312 
that is 95% similar at nucleotide and 97% similar at amino acid level. As the strain analyzed 313 
in our study was isolated from a farm located close to the Slovakian border, and since no 314 
other related strains from independent locations were present in public and private databases, 315 
this virus is the most likely recent ancestor giving rise to the family of isolates including 316 
PRRSV-2/Hungary/102/2012, HU12 (DQ366650) and HU21 (EF406336). The latter two 317 
isolates from 2005 showed only 3% nucleotide and 1% amino acid differences in comparison 318 
to PRRSV-2/Hungary/102/2012. This relatively slow rate of evolution in one of the most 319 
variable part of the PRRSV genome might suggest that use of a type 1 modified live vaccine 320 
used in the herd to control endemic type 1 PRRSV did not provoke a strong selective pressure 321 
against the type 2 isolate. Hence, it remained conserved over a period of at least 7 years. 322 
 Although nsp2 insertions and deletions were present in the genome compared to 323 
JAX1 and VR2332, unusual characteristics of pathogenicity or infectivity were not observed 324 
under field conditions. However, exact statements on these parameters can only be given after 325 
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controlled challenge studies. Whether these deletions and the insertion had a negative effect 326 
on tissue tropism, growth rate and/or speed of the genetic change of PRRSV-327 
2/Hungary/102/2012 further investigations are needed. 328 
 Antigenic regions of GP2 are relatively conserved, so it is likely that they are 329 
functionally important and PRRSV does not tolerate amino acid changes in these regions. The 330 
majority of amino acid changes among the investigated strains are positioned in the N-331 
terminal (GP21-40) and the C-terminal (GP2240-256) regions of GP2. The N-terminal region 332 
contains a hydrophobic stretch of amino acids (GP227-40) that has the potential to be a 333 
conditional membrane binding site and/or part of a signal peptide. Although mutations are 334 
common in this region, the physicochemical character of the protein remains well conserved, 335 
reinforcing the putative functional significance of this site. Similar hypermutability with 336 
conserved physicochemical characters can be observed in the amino-terminal hydrophobic 337 
regions of all GP proteins (GP31-30, GP41-20 and GP51-31) and all of them are signal peptides 338 
(Das et al., 2010; Thaa et al., 2013; Meulenburg, 2000; Kim et al., 2013). The N-glycan 339 
addition at N184 in GP2 is critical for recovery of infectious virus but the lack of glycan in 340 
N178 does not effect virus growth (Das et al., 2010). A mutation was found within the 341 
glycosylation recognition sequence of N184 in PRRSV-2/Hungary/102/2012 compared to the 342 
reference strains but this change most probably does not inhibit glycosylation of the site. 343 
 Excluding AR137-159, the predicted B cell epitopes of GP3 are conserved. The reasons 344 
for conservation might be similar to those of GP2. A previous study demonstrated that six 345 
sites (Das et al., 2010) of GP3 have glycan moieties from seven potential N-linked 346 
glycosylation sites, and N195 is not used for glycosylation. All glycosylation sites are present 347 
on GP3 of PRRSV-2/Hungary/102/2012. Mutations are present in two motifs (N29 and N152), 348 
but are not likely to affect the glycosylation status. 349 
 AR51-65, a hypervariable region in GP4, is considered as neutralization epitope in type 350 
1 PRRSV Lelystad virus. Previous studies have demonstrated that this epitope is susceptible 351 
to monoclonal antibody-induced immunoselection in vitro (Costers et al., 2010), thus 352 
explaining the high variability of this antigenic region. The conserved C terminal anchor 353 
(GP3181-197) of GP3 overlaps with the variable N-terminus of GP4, which serves as a signal 354 
peptide and contain a T-cell epitope (Tce7-15). Interestingly, similar overlaps can be observed 355 
between the conserved GP2 C-terminal membrane anchor (GP2210-232) and the hypervariable 356 
N-terminal signal peptide of GP3. This sequence pattern suggests that the amino acids in 357 
membrane anchors of GP2 and GP3 have additional sequence specific functions (e.g. protein-358 
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protein interaction) because the anchor function alone does not necessitate sequential 359 
conservation.  360 
 All the four potential glycosylation sites of GP4 of VR2332 were shown to be 361 
glycosylated. GP4 of PRRSV-2/Hungary/102/2012 contains a fifth N-glycosylation site (N57) 362 
in the AR51-65. It can be speculated that this potential glycosylation site might function as an 363 
anchor point for glycan shielding.  364 
 AR1-15 within GP5 is part of signal peptide which is cleaved during peptide processing. 365 
AR27-35 may function as a decoy epitope, which is hypervariable and is not involved in 366 
neutralization. However, recently it has experimentally been proved, that this epitope is only 367 
present at very low frequencies as a result of an alternative cleavage site of the signal peptide 368 
after the aa 26. (Ostrowski et al., 2002; Thaa et al., 2013). A previous study has demonstrated 369 
that aa positions at 32, 33 and 34 of GP5 are under significant positive selection (Delisle et al., 370 
2012). AR27-35 contains a functional glycosylation site N34 in NVSL 97-7895, while three 371 
potential sites (N30 N34 and N35) can be found in the same region of PRRSV-372 
2/Hungary/102/2012. N30, N34 and N35, together with the highly conserved N44 and N51 373 
compose a very rare combination of N-glycosylation sites on the GP5 of type 2 PRRSVs, less 374 
than 1% of the strains contain this pattern (Delisle et al., 2012). The close proximity of N30, 375 
N34 and N35 makes it improbable (because of steric inhibition) that all the three sites would 376 
be glycosylated together on the same GP5 molecule of PRRSV-2/Hungary/102/2012. On the 377 
other hand, considering the positive selection pressure in the region (Delisle et al., 2012), it is 378 
also unlikely that the presence of the three glycosylation sites on GP5 would be just a 379 
functionless arbitrary event. Most probably these sites are glycosylated in several 380 
combinations on different GP5 molecules that compose a set of glycoforms in the PRRSV-381 
2/Hungary/102/2012 envelope similarly as it was shown in the VR2332 virion (Thaa et al., 382 
2013). Alternatively, it cannot be excluded that glycosylation patterns are not under selection, 383 
but instead are derivative to changes in ORF5a (Robinson et al., 2013). 384 
As a large majority of the amino acid alterations in GP4 and GP5 of our isolate were 385 
found in the previously described antigenic regions, we hypothesize that immunological 386 
pressure played an important role in the evolution of the virus. It is possible that an early, fast 387 
evolution period might have occurred in the early 2000’s when an exponential increase in 388 
genetic diversity has been observed among type 2 strains (Shi et al. 2010b). Similar strains 389 
were first identified in 2005 by our research team (Balka et al., 2008), and anecdotal 390 
information suggested the import of boars from Canada to the herd in previous years. The 391 
comparison of these early strains and the recent isolate revealed the slowing down of the 392 
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genetic change as only 1% amino acid change occurred in the ORF5 ectodomain in the 7 393 
years between initial sequencing and the recent viral isolation in 2012. These findings indicate 394 
a biphasic evolution with a fast, early developmental stage, when the virus may have been 395 
surrounded by other type 2 isolates, and a second slower phase after the virus was introduced 396 
to this region, and was not influenced by immunity against other type 2 strains. 397 
We conclude that PRRSV-2/Hungary/102/2012 is the first type 2 PRRSV isolated in 398 
Europe that belongs to the lineage 1 or 2, and unlike every other European type 2 strain, it is 399 
proved to be not related to the Ingelvac MLV. Lineages 1 and 2 were exclusively formed by 400 
North American sequences until now. These data suggest that the strain was imported directly 401 
from North America during the early stages of PRRSV diversification (most likely from 402 
Canada or the North Central USA), and the divergent evolution of the viruses in the two 403 
continents resulted in marked genetic differences among PRRSV-2/Hungary/102/2012 and 404 
other type 2 viruses. 405 
 406 
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Figure legends 592 
 593 
Figure 1. 594 
Molecular phylogenetic analysis of PRRSV whole genomes by maximum likelihood method. 595 
Lineage designations are from Shi et al., 2010b.  596 
 597 
Figure 2. 598 
Maximum likelihood phylogenetic trees for PRRSV-2/Hungary/102/2012 ORF5 (A.) 599 
designations are from Shi et al., 2010b. (B.) Representative lineage 1 and 2 sequences 600 
including closest Genbank BLAST hits to PRRSV-2/Hungary/102/2012 (arrow). Closed 601 
circles are all sequences with 92% sequence similarity. Open circle has 91% similarity. MB 602 
CA: Manitoba, Canada; MN, Minnesota; AR, Arkansas; ?, source not provided in Genbank. 603 
 604 
Figure 3. 605 
Insertion/deletion analysis of PRRSV-2/Hungary/102/2012 by the alignment to the type 2 606 
prototype strain VR2332 and the Chinese highly pathogenic reference strain JXA-1. 607 
(A) Whole genome sequence schematic with open reading frames (B) Expanded view of the 608 
nsp2 nucleotide sequence region showing insertions and deletions (C) Amino acid sequence 609 
analysis of nsp2 ORF insertion and deletion pattern. 610 
 611 
Figure 4. 612 
Alignments and analysis of envelope glycoproteins (GP) 2, 3, 4, and 5 of isolates PRRSV-613 
2/Hungary/102/2012, VR2332, Ch-1a and NVSL 97-7895. Experimentally confirmed and 614 
identifiable B-cell epitopes are highlighted by grey boxes. Antigenic regions (AR) are 615 
numbered by position. The overlapping regions of ARs are highlighted by dark grey boxes. 616 
(A.) GP2. Experimentally confirmed glycolysation sites are underlined and set in bold (de 617 
Lima et al., 2006; Vanhee et al.,2011; Das et al., 2010). (B.) GP3. Experimentally confirmed 618 
glycosylation sites are underlined and set in bold (de Lima et al., 2006; Das et al., 2010; Zhou 619 
et al, 2006; Wang et al., 2014). (C.) GP4. Potential glycosylation sites are underlined and 620 
experimentally confirmed sites are set in bold (de Lima et al., 2006; Das et al., 2010;Diaz et 621 
al., 2009; Costers et al., 2010). (D.) GP5. Antigenic regions (AR) are numbered by position. T 622 
cell epitopes (Tce) are highlighted by open boxes. Potential glycosylation sites are underlined, 623 
the experimentally confirmed ones are set in bold (de Lima et al., 2006; Diaz et al., 2009; 624 
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Plagemann et al., 2002; Ostrowski et al., 2002; Zhou et al., 2009; Mokhtar et al., 2014; 625 
Vashisht et al., 2008). 626 
 627 
Table 1. Oligonucleotide primers used for RT-PCR amplification of PRRSV-628 
2/Hungary/102/2012. 629 
 630 
Table 2. List of full genome sequences used for the phylogenetic analyses and tree 631 
reconstruction. 632 
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Molecular phylogenetic analysis of PRRSV whole genomes by maximum likelihood method. Lineage 
designations are from Shi et al., 2010b.  
171x53mm (300 x 300 DPI)  
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Maximum likelihood phylogenetic trees for PRRSV-2/Hungary/102/2012 ORF5 (A.) designations are from Shi 
et al., 2010b.  
104x254mm (300 x 300 DPI)  
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Maximum likelihood phylogenetic trees for PRRSV-2/Hungary/102/2012 ORF5 (B.) Representative lineage 1 
and 2 sequences including closest Genbank BLAST hits to PRRSV-2/Hungary/102/2012 (arrow). Closed 
circles are all sequences with 92% sequence similarity. Open circle has 91% similarity. MB CA: Manitoba, 
Canada; MN, Minnesota; AR, Arkansas; ?, source not provided in Genbank.  
164x229mm (150 x 150 DPI)  
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Insertion/deletion analysis of PRRSV-2/Hungary/102/2012 by the alignment to the type 2 prototype strain 
VR2332 and the Chinese highly pathogenic reference strain JXA-1.  
(A) Whole genome sequence schematic with open reading frames (B) Expanded view of the nsp2 nucleotide 
sequence region showing insertions and deletions (C) Amino acid sequence analysis of nsp2 ORF insertion 
and deletion pattern.  
 
258x61mm (300 x 300 DPI)  
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Alignments and analysis of envelope glycoproteins (GP) 2, 3, 4, and 5 of isolates PRRSV-
2/Hungary/102/2012, VR2332, Ch-1a and NVSL 97-7895. Experimentally confirmed and identifiable B-cell 
epitopes are highlighted by grey boxes. Antigenic regions (AR) are numbered by position. The overlapping 
regions of ARs are highlighted by dark grey boxes. (A.) GP2. Experimentally confirmed glycolysation sites 
are underlined and set in bold (de Lima et al., 2006; Vanhee et al.,2011; Das et al., 2010). (B.) GP3. 
Experimentally confirmed glycosylation sites are underlined and set in bold (de Lima et al., 2006; Das et al., 
2010; Zhou et al, 2006; Wang et al., 2014). (C.) GP4. Potential glycosylation sites are underlined and 
experimentally confirmed sites are set in bold (de Lima et al., 2006; Das et al., 2010;Diaz et al., 2009; 
Costers et al., 2010). (D.) GP5. Antigenic regions (AR) are numbered by position. T cell epitopes (Tce) are 
highlighted by open boxes. Potential glycosylation sites are underlined, the experimentally confirmed ones 
are set in bold (de Lima et al., 2006; Diaz et al., 2009; Plagemann et al., 2002; Ostrowski et al., 2002; 
Zhou et al., 2009; Mokhtar et al., 2014; Vashisht et al., 2008).  
327x216mm (150 x 150 DPI)  
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Primer Sequence Position 
PR_USA_1F  ATGACGTATAGGTGTTGGCTCTATG 1-25 
PR_USA_3358R CAAGCTTAGTCGCATCACATGCCTC 3334-3358 
PR_USA_3248F ACTCAGCTCAAGCCATCATCGACTC 3248-3272 
PR_USA_6709R CAGAGAACACTCCATCGCCAACAAG 6685-6709 
PR_USA_6408F GTCTGCGCAAGTTCTGATGATCAGG 6408-6432 
PR_USA_9230R ATACAGCACGAGGTCGTCCGAATAG 9206-9230 
PR_USA_9018F GTGACTAAGAGAGGTGGCCTGTCGT 9018-9042 
PR_USA_12972R GGAATCCTAGCTCGTCATGATCGTC 12948-12972 
PR_USA_12827F CTTCGAGCTCACGGTGAATTACACG 12827-12851 
Pr15_USA_15397R  GGTTCTCGCCAATTAAATCTCACCC 15373-15397 
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ID Genebank Accession No. Strain name Country
PRRSV2/CHN/NJ-1106/2012JX880029 NJ-1106 CHN
PRRSV2/USA/JA142/2004 AY424271 JA142 USA
PRRSV2/KOR/PL97-1/1997 AY585241 PL97-1 KOR
PRRSV2/USA/NVSL97-7985/1997AF325691 NVSL 97-7985 IA 1-4-2 USA
PRRSV2/CHN/DC/2010 JF748718 DC CHN
PRRSV2/CHN/YD/2009 JF748717 YD CHN
PRRSV2/CHN/SD0901 JN256115 SD0901 CHN
PRRSV2/CHN/SD-CXA/2009GQ359108 SD-CXA/2008 CHN
PRRSV2/CHN/CH-1a/1999 AY032626 CH-1a CHN
PRRSV2/CHN/BJ-4/2000 AF331831 BJ-4 CHN
PRRSV2/CHN/Henan-A8/2013KJ534543 Henan-A8 CHN
PRRSV2/CHN/XJu-1/2012 KF815525 XJu-1 CHN
PRRSV2/CHN/HZ-31/2012 KC445138 HZ-31 CHN
PRRSV1/CHN/NVDC-NM1-2011/2011JX187609 NVDC-NM1-2011 CHN
PRRSV2/CHN/YN-2011/2011JX857698 YN-2011 CHN
PRRSV2/CHN/GX1002/2010JQ955658 GX1002 CHN
PRRSV2/CHN/JXM80/2008 GQ499196 JXM80 CHN
PRRSV2/CHN/SDA3/2011 JX878380 SDA3 CHN
PRRSV2/CHN/SCwhn09CD/2009JN836553 SCwhn09CD CHN
PRRSV2/CHN/QYYZ/20011 JQ308798 QYYZ CHN
PRRSV2/CHN/GM2/2011 JN662424 GM2 CHN
PRRSV2/CHN/SD16/2012 JX087437 SD16 CHN
PRRSV2/CHN/QY2010/2010JQ743666 QY2010 CHN
PRRSV2/CHN/NVDC-JS2-2011/2011JQ715698 NVDC-JS2-2011 CHN
PRRSV2/CHN/NVDC-GD2-2011/2011JQ715697 NVDC-GD2-2011 CHN
PRRSV2/CHN/WUH4/2011 JQ326271 WUH4 CHN
PRRSV2/USA/VR2332/1995PRU87392 ATCC VR-2332 USA
PRRSV1/CHN/NMEU09-1/2009GU047345 NMEU09-1 CHN
PRRSV1/CHN/BJEU06-1/2006GU047344 BJEU06-1 CHN
PRRSV2/CHN/GDQY/2007 GU454850 GDQY2 CHN
PRRSV2/CHN/AH0701/2007GU461292 AH0701 CHN
PRRSV1/CHN/Amervac GU067771 Amervac CHN
PRRSV1/NLD/MLV-DV/1999KJ127878 MLV-DV NLD
PRRSV2/DEN/DK-2011-88005-A8-Pl/2011KF183947 DK-2011-88005-A8-Pl DEN
PRRSV2/DEN/DK-2010-10-13-1/2010KF 83946 DK-2010-10-13-1 DEN
PRRSV2/KOR/CA-2/2013 KF555450 CA-2 KOR
PRRSV1/HUN/9625/2012 KJ415276 9625/2012 HUN
PRRSV2/CHN/HENAN-HEB KJ143621 HENAN-HEB CHN
PRRSV1/ESP/Olot-91/1991 KF203132 Olot/91 ESP
PRRSV2/DEN/DK-2004-2-1/2004KC862585 DK-2004-2-1 DEN
PRRSV2/DEN/DK-2003-2-3/2003KC862584 DK-2003-2-3 DEN
PRRSV2/DEN/DK-2010-10-4-1/2010KC862583 DK-2010-10-4-1 DEN
PRRSV2/DEN/DK-2008-10-1-3/2008KC862582 DK-2008-10-1-3 DEN
PRRSV2/DEN/DK-1997-19407B/1997KC862576 DK-1997-19407B DEN
PRRSV2/DEN/DK-2012-01-11-3/2012KC862575 DK-2012-01-11-3 DEN
PRRSV1/DEN/DK-2003-7-2/2003KC862572 DK-2003-7-2 DEN
PRRSV1/DEN/DK-2011-05-23-9/2011KC862569 DK-2011-05-23-9 DEN
PRRSV1/DEN/DK-2010-10-10-3/2010KC862568 DK-2010-10-10-3 DEN
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PRRSV1/DEN/DK-1992-PRRS-111_92/1992KC862566 DK-1992-PRRS-111_92 DEN
PRRSV2/VNM/SRV07/2007JX512910 SRV07 VNM
PRRSV2/USA/SD95-21/1995KC469618 SD95-21 USA
PRRSV2/CHN/BB0907/2009HQ315835 BB0907 CHN
PRRSV2/CHN/GD-2011/2011KC527830 GD-2011 CHN
PRRSV2/USA/NADC30/2008JN654459 NADC30 USA
PRRSV2/USA/SDSU73 JN654458 SDSU73 USA
PRRSV2/CHN/JX JX317649 JX CHN
PRRSV2/CHN/HV JX317648 HV CHN
PRRSV2/USA/A2MC2 JQ087873 A2MC2 USA
PRRSV2/CHN/09HUB2/2009JF268683 09HUB2 CHN
PRRSV2/CHN/09HEN1/2009JF268684 09HEN1 CHN
PRRSV2/CHN/09DB2/2009 JF268681 09DB2 CHN
PRRSV2/CHN/09HEB/2009 JF268679 09HEB CHN
PRRSV2/CHN/09SD/2009 JF268678 09SD CHN
PRRSV2/CHN/09BJ/2009 JF268676 09BJ CHN
PRRSV2/CHN/09JS/2009 JF268675 09JS CHN
PRRSV2/CHN/09HUN1/2009JF268673 09HUN1 CHN
PRRSV2/CHN/09SC/2009 JF268672 09SC CHN
PRRSV2/CHN/SX-1/2009 GQ857656 SX-1 CHN
PRRSV2/CHN/SY0909/2009HQ315837 SY0909 CHN
PRRSV2/CHN/NT0801/2008HQ315836 NT0801 CHN
PRRSV2/CHN/BJ0706/2007GQ351601 BJ0706 CHN
PRRSV1/USA/EuroPRRSV/1999AY366525 EuroPRRSV USA
PRRSV2/CHN/HN-HW/2006FJ797690 HN-HW CHN
PRRSV2/USA/VR2332a AY150564 VR-2332a USA
PRRSV2/CHN/HN1 AY457635 HN1 CHN
PRRSV2/USA/MLV AF159149 MLV RespPRRS/Repro USA
PRRSV2/CHN/LN1101 KF751238 LN1101 CHN
PRRSV2/CHN/BJ1102/2011KF751237 BJ1102 CHN
PRRSV2/CHN/SH1211/2012KF678434 SH1211 CHN
PRRSV1/CHN/NVDC-NM3 KC492505 NVDC-NM3 CHN
PRRSV2/CHN/HENAN-XINX/2013KF611905 HENAN-XINX CHN
PRRSV2/CHN/HK12/2004 KF287139 HK12 CHN
PRRSV2/CHN/HK4/2003 KF287134 HK4 CHN
PRRSV1/CHN/GZ11-G1/2011KF001144 GZ11-G1 CHN
PRRSV2/CHN/11GZ-GD/2011JX235370 11GZ-GD CHN
PRRSV2/CHN/10HD-GD/2010JX215553 10HD-GD CHN
PRRSV2/CHN/JL-0412/2012JX177644 JL-04/12 CHN
PRRSV2/LAO/10-LW8-1/2010JQ663568 10-LW8-1 LAO
PRRSV2/CHN/10-10GX-5/2010JQ663562 10-10GX-5 CHN
PRRSV2/VNM/10-10QN/2010JQ663556 10-10QN VNM
PRRSV2/CHN/10-10SD/2010JQ663555 10-10SD CHN
PRRSV2/CHN/10-10JL/2010JQ663554 10-10JL CHN
PRRSV2/CHN/10-10HEB-3/2010JQ663553 10-10HEB-3 CHN
PRRSV2/CHN/10-10FUJ-1/2010JQ663546 10-10FUJ-1 CHN
PRRSV2/CHN/10-10BJ-1/2010JQ663541 10-10BJ-1 CHN
PRRSV2/CHN/10-10JX/2010JQ663540 10-10JX CHN
PRRSV2/CHN/09HUB7/2009GU168567 09HUB7 CHN
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PRRSV2/CHN/GX10-48/2006JQ309823 GX10-48 CHN
PRRSV2/USA/NC16845/2006HQ699067 NC16845 USA
PRRSV2/CHN/DY/2007 JN864948 DY CHN
PRRSV2/CHN/HLJHL/2009 HM189676 HLJHL CHN
PRRSV2/CHN/GX09-16/2009HM214913 GX09-16 CHN
PRRSV2/CHN/JN-HS2008 HM016158 JN-HS CHN
PRRSV2/CHN/ZP-1/2009 HM016159 ZP-1 CHN
PRRSV2/CHN/GDBY1/2008 GQ374442 GDBY1 CHN
PRRSV2/CHN/GDQJ/2007 GQ374441 GDQJ CHN
PRRSV2/CHN/GD3/2005 GU269541 GD3 CHN
PRRSV2/CHN/SD1-100 GQ914997 SD1-100 CHN
PRRSV2/CHN/KP GU232735 KP CHN
PRRSV2/CHN/08SDWF/2008GU168569 08SDWF CHN
PRRSV1/THA/01CB1/2001 DQ864705 01CB1 THA
PRRSV2/KOR/PL97-1-LP1/1997AY612613 PL97-1/LP1 KOR
PRRSV2/CHN/Em2007/2007EU262603 Em2007 CHN
PRRSV2/CHN/GS2004/2004EU880443 GS2004 CHN
PRRSV2/CHN/NX06 EU097706 NX06 CHN
PRRSV2/CHN/BJsy06/2006 EU097707 BJsy06 CHN
PRRSV2/CHN/CC-1 EF153486 CC-1 CHN
PRRSV2/USA/Prime Pac/1996DQ779791 Prime Pac USA 
PRRSV2/USA/MN184B DQ176020 MN184B USA
PRRSV2/USA/MN184A DQ176019 MN184A USA
PRRSV2/CHN/XH-GD EU624117 XH-GD CHN
PRRSV2/KOR/LMY/2002 DQ473474 LMY KOR
PRRSV2/CHN/CH-1R EU807840 CH-1R CHN
PRRSV2/USA/Ingelvac ATP DQ988080 Ingelvac ATP USA
PRRSV1/KOR/KNU-07/2007FJ349261 KNU-07 KOR
PRRSV2/CHN/SY0608/2006EU144079 SY0608 CHN
PRRSV2/CHN/WUH3/2008 HM853673 WUH3 CHN
PRRSV2/CHN/08HuN/2008 GU169411 08HuN CHN
PRRSV2/CHN/HB-1(sh)/2001AY150312 HB-1(sh)/2002 CHN
PRRSV2/CHN/CWZ-1-F3/2008FJ889130 CWZ-1-F3 CHN
PRRSV2/CHN/PRRSV03 FJ175689 PRRSV03 CHN
PRRSV2/CHN/GD/2007 EU825724 GD CHN
PRRSV2/CHN/BJ/2007 EU825723 BJ CHN
PRRSV2/CHN/HPBEDV EU236259 HPBEDV CHN
PRRSV2/CHN/Henan-1 EU200962 Henan-1 CHN
PRRSV2/CHN/Jiangxi-3 EU200961 Jiangxi-3 CHN
PRRSV2/USA/MN/MN184CEF488739 MN184C USA
PRRSV2/VNM/07QN/2007 FJ394029 07QN VNM
PRRSV2/CHN/GD/2006 EU109503 GD CHN
PRRSV2/CHN/LN/2006 EU109502 LN CHN
PRRSV2/CHN/SHH/2006 EU106888 SHH CHN
PRRSV2/CHN/HEB1/2006 EF112447 HEB1 CHN
PRRSV2/CHN/HUN2/2006 EF112446 HUB2 CHN
PRRSV2/USA/MFF_After EF532819 MFF_After USA
PRRSV2/USA/Lewis_BeforeEF532818 Lewis_Before USA
PRRSV2/USA/Lewis_After EF532817 Lewis_After USA
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PRRSV2/USA/ISU-P EF532816 ISU-P USA
PRRSV2/USA/Hawkeye7_BeforeEF532815 Hawkeye7_Before USA
PRRSV2/USA/Hawkeye7_AfterEF532814 Hawkeye7_After USA
PRRSV2/USA/Hawkeye4_BeforeEF532813 Hawkeye4_Before USA
PRRSV2/USA/Hawkeye4_AfterEF532812 Hawkeye4_After USA
PRRSV2/USA/Hawkeye2_BeforeEF532811 Hawkeye2_Before USA
PRRSV2/USA/Hawkeye2_AfterEF532810 Hawkeye2_After USA
PRRSV2/USA/FF4_After EF532809 FF4_After USA
PRRSV2/USA/FF3_Before EF532808 FF3_Before USA
PRRSV2/USA/FF2_After EF532807 FF2_After USA
PRRSV2/USA/FF1_Before EF532806 FF1_Before USA
PRRSV2/USA/Flagship_BeforeEF532805 Flagship_Before USA
PRRSV2/USA/Flagship_AfterEF532804 Flagship_After USA
PRRSV2/USA/Biss_Before EF532803 Biss_Before USA
PRRSV2/USA/Biss_After EF532802 Biss_After USA
PRRSV2/CHN/JSyx/2006 EU939312 JSyx CHN
PRRSV2/CHN/SX2009/2009FJ895329 SX2009 CHN
PRRSV2/CHN/07BJ/2007 FJ393459 07BJ CHN
PRRSV2/CHN/07HEBTJ/2007FJ393458 07HEBTJ CHN
PRRSV2/CHN/07HEN/2007 FJ393457 07HEN CHN
PRRSV2/CHN/07NM/2007 FJ393456 07NM CHN
PRRSV2/CHN/TP/2006 EU864233 TP CHN
PRRSV2/CHN/SHB/2005 EU864232 SHB CHN
PRRSV2/CHN/CG/2007 EU864231 CG CHN
PRRSV2/USA/VR2332 EF536003 VR2332 USA
PRRSV2/USA/QUAL2_AfterEF536002 QUAL2_After USA
PRRSV2/USA/QUAL1_BeforeEF536001 QUAL1_Before USA
PRRSV2/USA/MN30100 EF536000 MN30100 USA
PRRSV2/USA/MFF_Before EF535999 MFF_Before USA
PRRSV2/CHN/HUN4 EF635006 HUN4 CHN
PRRSV2/CHN/JXA1/2006 EF112445 JXA1 CHN
PRRSV2/NED/Lelystad virusM96262 Lelystad virus NED
PRRSV2/USA/MN9A/2012 MN9A USA
PRRSV2/USA/MN9B/2012 MN9B USA
PRRSV2/USA/IA12/2012 IA12 USA
PRRSV2/USA/MN15/2012 MN15 USA
PRRSV2/USA/MN5/2012 MN5 USA
PRRSV2/USA/MN4/2012 MN4 USA
PRRSV2/USA/MN3/2012 MN3 USA
PRRSV2/USA/MN1/2012 MN1 USA
PRRSV2/USA/MN11A/2012 MN11A USA
PRRSV2/USA/MN6/2012 MN6 USA
PRRSV2/USA/MN14/2012 MN14 USA
PRRSV2/USA/MN2/2012 MN2 USA
PRRSV2/USA/MN11B/2012 MN11B USA
PRRSV2/USA/MN7/2012 MN7 USA
PRRSV2/USA/IL8/2012 IL8 USA
PRRSV2/USA/MN16/2011 MN16 USA
PRRSV2/USA/MN17A/2012 MN17A USA
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PRRSV2/USA/MN17B/2013 MN17B USA
PRRSV2/USA/BI- Sample 1 BI- Sample 1 USA
PRRSV2/USA/BI- Sample 2 BI- Sample 2 USA
PRRSV2/USA/JZ1 JZ1 USA
PRRSV2/USA/JZ4 JZ4 USA
PRRSV2/USA/JA1262 JA1262 USA
PRRSV2/USA/AL27 AL27 USA
PRRSV2/USA/EP37 EP37 USA
PRRSV2/USA/1-2-3 Yeske 1-2-3 Yeske USA
PRRSV2/USA/Cleeny West Cleeny West USA
PRRSV2/USA/E32 E32 USA
PRRSV2/USA/JZ2 JZ2 USA
PRRSV2/USA/JZ8 JZ8 USA
PRRSV2/USA/Mt. Echo Mt. Echo USA
PRRSV2/USA/K9/2009 K9 (Kingston 2009) USA
PRRSV2/USA/K10/2010 K10 (Kingston 2010) USA
PRRSV2/USA/K11/2011 K11 (Kingston 2011) USA
PRRSV2/USA/K12/2012 K12 (Kingston 2012) USA
PRRSV2/USA/Bon Homme (Spronk) Bon Homme (Spronk) USA
PRRSV2/USA/1784 (IA) 1784 (IA) USA
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Region Year
Nanjing 2012
2004
1997
Iowa 1997
Guangzhou 2010
Guangzhou 2009
2009
1999
2000
Henan 2013
Xinjiang 2012
Hubei 2012
2011
Yunnan 2011
Guangxi 2010
Shangai 2008
2011
Sichuan 2009
Guangdong 2011
Guangdong 2011
2012
Guangdong 2010
Jiangsu 2011
Guangdong 2011
2011
1995
Inner Mongolia 2009
Beijing 2006
Guangdong 2007
Anhui 2007
1999
2011
2010
2013
2012
2012
1991
2004
2003
2010
2008
1997
2012
2003
2011
2010
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35
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40
41
42
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45
46
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48
49
50
51
52
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54
55
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57
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1992
2007
South Dakota 1995
Guangxi 2009
2011
Iowa 2008
1996
2010
2007
2010
Hubei 2009
Henan 2009
Dongbei 2009
Hebei 2009
Shandong 2009
Beijing 2009
Jiangsu 2009
Hunan 2009
Sichuan 2009
Shanxi 2009
Jiangsu 2009
Jiangsu 2008
Beijing 2007
Iowa 1999
Hunan 2006
Liaoning 2011
Beijing 2011
Shanghai 2012
2011
Henan 2013
HongKong 2004
HongKong 2003
Guangdong 2011
Guangdong 2011
Guangdong 2010
Jilin 2012
2010
Guangxi 2010
2010
Shandong 2010
Jilin 2010
Hebei 2010
Fujian 2010
Beijing 2010
Jiangxi 2010
Hubei 2009
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31
32
33
34
35
36
37
38
39
40
41
42
43
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45
46
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Guangxi 2006
North Carolina 2006
2007
Heilongjiang 2009
Guangxi 2009
Shandong 2008
Shandong 2009
Guangdong 2008
Guangdong 2007
Guangdong 2005
Guangdong
2008
Chonburi 2001
1997
2007
2007
2006
Beijing 2006
1996
Guangdong
2002
2007
2006
2008
Hunan 2008
Hebei 2001
Chongqing 2008
Guangdong 2007
Beijing 2007
Henan
Jiangxi
MN
Quang Nam 2007
Guangdong 2006
Liaoning 2006
Shanghai 2006
Hebei 2006
Hubei 2006
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59
60
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2005
2005
2006
Shanxi 2009
Beijing 2007
Heibei 2007
Henan 2007
Neimeng 2007
Guangdong 2006
Guangdong 2005
Guangdong 2007
Hunan
Jiangxi 2006
Minnesota 2012
Minnesota 2012
Iowa 2012
Minnesota 2012
Minnesota 2012
Minnesota 2012
Minnesota 2012
Minnesota 2012
Minnesota 2012
Minnesota 2012
Minnesota 2012
Minnesota 2012
Minnesota 2012
Minnesota 2012
Illinois 2012
Minnesota 2011
Minnesota 2012
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35
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Minnesota 2013
Minnesota 2009
Minnesota 2010
Minnesota 2011
Minnesota 2012
Minnesota
Iowa
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